“A pressing need exists for affordable and accessible testing in dementia care,” stated Joel Braunstein, MD, CEO of C2N. “We are highly appreciative of GHR Foundation’s partnership. With their support, GHR is enabling a future that positively impacts the fate of Alzheimer’s in people at risk for the disease. Earlier detection will improve clinical care and facilitate new ways to change the course of disease through treatment and prevention.”
C2N expects to soon be able to provide practicing clinicians with a blood test that they can order for their patients who are showing early signs of memory loss. The test will help doctors determine the likelihood that Alzheimer’s pathology is present. In addition to supporting C2N’s launch of the APTUS-A™ test under CLIA, GHR’s funding will also fuel C2N’s global growth and pipeline of other neurologic diagnostic tests.
“C2N’s entrepreneurial mindset combined with their deep commitment to help patients are central to GHR’s goal of Alzheimer’s prevention,” stated Amy Goldman, CEO and Chair of GHR Foundation. “We are delighted to support the team and look forward to serving their potential as, together, we reimagine what’s possible in preventing this disease.”